Results 151 to 160 of about 3,667 (197)
Microbes and Infection, 2006 International audiencePlasmodium falciparum resistance to atovaquone-proguanil has so far been associated with Y268S or Y268N mutations in cytochrome b, although these changes were identified in only seven of the 11 treatment failures.
Lise Musset +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2017
Atovaquone was the first hydroxynaphthoquinone suitable for the treatment of Plasmodium falciparum infection (Davies et al., 1989). Unfortunately, early treatment failure rates were as high as 30% (Looareesuwan et al., 1996; Chiodini et al., 1995); among those who had recrudescent infection, parasites were approximately 1000- to 10000-fold more ...
openaire +3 more sources
Atovaquone was the first hydroxynaphthoquinone suitable for the treatment of Plasmodium falciparum infection (Davies et al., 1989). Unfortunately, early treatment failure rates were as high as 30% (Looareesuwan et al., 1996; Chiodini et al., 1995); among those who had recrudescent infection, parasites were approximately 1000- to 10000-fold more ...
openaire +3 more sources
Atovaquone—Proguanil Combination
2001Development of an atovaquone—proguanil combination, trademarked Malarone, during the 1990s has been a major step in addressing the need for antimalarial drugs with targets different from those of agents for which resistance is already rampant in the field (1).
openaire +1 more source
▼Atovaquone + proguanil for malaria prophylaxis
Drug and Therapeutics Bulletin, 2001▼Atovaquone + proguanil* (Malarone - GlaxoSmithKline) is a fixed-dose combination of two antiparasitic drugs. In 1996, it was licensed in the UK for the treatment of acute, uncomplicated falciparum malaria. Earlier this year, the combination was licensed additionally for prophylaxis of falciparum malaria.
openaire +1 more source